Online inquiry

IVTScrip™ mRNA-Anti-FCGRT, UCB-7665(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15513MR)

This product GTTS-WQ15513MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets FCGRT gene. The antibody can be applied in Myasthenia Gravis (MG) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FCGRT, UCB-7665(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ15513MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12538MR IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA NPVPDR001
GTTS-WQ5137MR IVTScrip™ mRNA-Anti-IL1RAP, CAN-04(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CAN-04
GTTS-WQ13448MR IVTScrip™ mRNA-Anti-TNFRSF10B, PRO95780(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PRO95780
GTTS-WQ8338MR IVTScrip™ mRNA-Anti-TFRC, HN-66000(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HN-66000
GTTS-WQ7525MR IVTScrip™ mRNA-Anti-CLDN18, GC-182(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GC-182
GTTS-WQ15369MR IVTScrip™ mRNA-Anti-ENG, TRC-105(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA TRC-105
GTTS-WQ6515MR IVTScrip™ mRNA-Anti-ALCAM, CX-191(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CX-191
GTTS-WQ14978MR IVTScrip™ mRNA-Anti-IL17A, SHR-1314(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SHR-1314
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW